Developer docs
API playgroundTry for free, no card

Search company profiles

Pfizer

Full company profile

uuid0037xnt

Namestring
Pfizer
Legal namestring
Pfizer Limited
Websiteurl
pfizerindia.com
Company typeenum
Public
Founded yearint
1950
Descriptiontext

Pfizer Limited is the Indian subsidiary of U.S.-based Pfizer Inc., operating as a publicly listed pharmaceutical company (NSE ticker: PFIZER; BSE: 500680) with over 70 years of India operations since 1950. The company markets more than 150 products across 15 therapeutic areas through 4 key business categories, focusing on branded pharmaceuticals, vaccines, and therapeutics, with approximately 70% of India-sold products manufactured domestically. Pfizer Limited generated Q3 FY26 revenue of Rs 645.03 crore (up 19.8% YoY) and Q4 FY26 revenue of Rs 629 crore, operating with a zero-debt balance sheet, 63.46% ROCE, and 35%+ profit margins.

The company uses a hybrid go-to-market combining enterprise field sales targeting hospitals and healthcare professionals (supported by the PfizerPro.in portal) with an exclusive supply and marketing agreement with Cipla Limited for legacy brands Corex Dx, Corex LS, Dolonex, and Neksium. Recent strategic activity includes the December 2025 launch of Rimegepant ODT in the anti-migraine category, hospital partnerships for adult vaccination (Artemis Hospitals), and the Arogya Seva Kendras CSR initiative with Star Health and Piramal Swasthya covering 9 Indian states. Customer segments span end-patients across multiple therapeutic conditions, healthcare professionals served through dedicated medical-information channels, and specialty care patients in categories such as migraine. Pfizer Limited is operationally influenced by global Pfizer Inc. decisions, including a December 2025/FY26 personnel restructuring with Rs 41.73 crore in exceptional separation costs and parent-level divestiture of Haleon in March 2025.

Short descriptiontext

Pfizer Limited is the Indian subsidiary of Pfizer Inc., marketing 150+ branded pharmaceutical products across 15 therapeutic areas, including vaccines and specialty therapeutics, serving Indian patients and healthcare professionals through field sales, the PfizerPro.in portal, and a Cipla distribution partnership.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
10,001+
akta.pro rankint
HeadquartersMumbai, India
HQ citystring
Mumbai
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, prescription medicines, vaccines and therapeutics, branded generic drugs, anti-migraine therapy
Industry4 codes
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Manufacturing
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pfizer India generates revenue through the sale of pharmaceutical products across 15 therapeutic areas with over 150 products in 4 key business categories. The company has a strong focus on branded products, vaccines, and therapeutics.

business-standard.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Pfizer Limited manufactures and markets a portfolio of more than 150 pharmaceutical products across 15 therapeutic areas through 4 key business categories, including branded medicines, vaccines, and therapeutics. Its offerings include the anti-migraine medication Rimegepant ODT launched in December 2025 and brands such as Corex Dx, Corex LS, Dolonex, and Neksium distributed through an exclusive supply and marketing agreement with Cipla.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 19.8% YoY revenue growth in Q3FY26
+3 more records
Product overview1 text field

Pfizer Limited operates as a pharmaceutical company offering a diverse portfolio of over 150 products across 15 therapeutic areas through 4 key business categories. The product portfolio includes branded pharmaceutical products such as migraine medication (Rimegepant ODT), and brands under strategic partnerships (Corex Dx, Corex LS, Dolonex, Neksium via Cipla agreement). The company focuses on vaccines and therapeutics, with products spanning multiple therapeutic categories.

Product and service6 records
1Rimegepant ODT
CategoryPharmaceutical Product
Description

Anti-migraine medication for adults with insufficient response to triptan drugs, sold to healthcare providers and dispensed to patients in India.

2Corex Dx
CategoryPharmaceutical Brand
Description

Pharmaceutical brand under exclusive supply and marketing agreement with Cipla Limited in India.

3Corex LS
CategoryPharmaceutical Brand
Description

Pharmaceutical brand under exclusive supply and marketing agreement with Cipla Limited in India.

4Dolonex
CategoryPharmaceutical Brand
Description

Pharmaceutical brand under exclusive supply and marketing agreement with Cipla Limited in India.

5Neksium
CategoryPharmaceutical Brand
Description

Pharmaceutical brand under exclusive supply and marketing agreement with Cipla Limited in India.

6Pfizer Limited Product Portfolio
CategoryCore Product Portfolio
Description

Comprehensive portfolio of more than 150 branded pharmaceutical products across 15 therapeutic areas and 4 key business categories, including vaccines, therapeutics, and other branded medicines sold to healthcare providers in India.

Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-25
Description

Pfizer India is contributing vaccination expertise to Star Health's Arogya Seva Kendras CSR program, providing free primary healthcare including adult pneumococcal vaccination. The initiative operates across 9 Indian states including Chennai, Mysuru, Hyderabad, Bhubaneswar, Punjab, UP, West Bengal, and Maharashtra.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-25
Description

Partnership with Piramal Swasthya for the Arogya Seva Kendras initiative under Star Health's CSR program to provide free primary healthcare services to over a million lives.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-19
Description

Exclusive supply and marketing agreement with Cipla Limited for Pfizer's brands Corex Dx, Corex LS, Dolonex, and Neksium. This partnership includes exceptional costs of Rs 41.73 crore for personnel separation linked to this agreement.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-02-24
Description

Pfizer to test Summit Therapeutics' bispecific with ADCs as part of cancer treatment development collaboration. Partnership evaluated for potential in cancer drug development.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-01-15
Description

Pfizer partnership with PAHO, Argentina, and Sinergium to drive local production of 20-valent pneumococcal vaccine for Latin America and the Caribbean.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-08-07
Description

Launch of Centre for Adult Vaccination with Artemis Hospitals, providing specialized vaccination services for adults including pneumococcal vaccination.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

India's largest domestic pharma company by some metrics and Pfizer India's exclusive distribution partner since December 2025 for Corex Dx, Corex LS, Dolonex, and Neksium. Directly comparable business model with branded generics across multiple therapeutic areas in India.

TypeDirect peer
Description

India-domiciled pharma with branded specialty/generic portfolio. Comparable in therapy-area breadth and HCP field-sales model, though typically positioned at a smaller revenue scale than Pfizer India.

TypeDirect peer
Description

Major Indian-headquartered pharma with a comparable branded generics portfolio plus emerging specialty/biologics presence. Competes directly with Pfizer India in cardiology, oncology, and primary care therapy areas.

TypeDirect peer
Description

Top-5 Indian pharma with branded and generic formulations across cardiovascular, diabetes, and respiratory areas. Directly comparable in scale, India-centric commercial model, and HCP-targeted field sales motion.

TypeDirect peer
Description

Mid-cap Indian pharma with branded formulations across therapeutic areas. Comparable in size, branded-generic strategy, and India-focused commercial execution to Pfizer Limited India.

6Sun Pharmaceutical Industries
TypeDirect peer
Description

India's largest pharmaceutical company by revenue, with a comparable branded formulations portfolio spanning multiple therapeutic areas. Both companies compete for the same HCP mind-share and retail pharmacy shelf space across India.

TypeDirect peer
Description

Indian subsidiary of Abbott Laboratories with a nearly identical structural profile to Pfizer Limited: MNC pharma subsidiary, broad therapy-area branded portfolio, and NSE/BSE-listed public company. Direct comparable for MNC pharma India model analysis.

8GSK Pharmaceuticals India (now part of Hetero/BSV)
TypeDirect peer
Description

MNC pharma subsidiary operating in India with branded specialty and vaccine portfolios. Closely mirrors Pfizer India's MNC pharma India business model, including vaccines and specialty launches.

TypeDirect peer
Description

Indian arm of Novartis with specialty pharma focus including neurology and cardiology. Comparable as a Swiss MNC pharma subsidiary operating in India with similar portfolio breadth and HCP-engagement model.

TypeDirect peer
Description

MNC pharma subsidiary with similar branded specialty franchises including diabetes/cardiovascular. Operates with comparable India-focused commercial structure, HCP sales force, and listed-entity dynamics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pfizer

Pharmaceutical Manufacturingpfizerindia.com

Pfizer Limited is the Indian subsidiary of Pfizer Inc., marketing 150+ branded pharmaceutical products across 15 therapeutic areas, including vaccines and specialty therapeutics, serving Indian patients and healthcare professionals through field sales, the PfizerPro.in portal, and a Cipla distribution partnership.

What Pfizer does

Pfizer Limited is the Indian subsidiary of U.S.-based Pfizer Inc., operating as a publicly listed pharmaceutical company (NSE ticker: PFIZER; BSE: 500680) with over 70 years of India operations since 1950. The company markets more than 150 products across 15 therapeutic areas through 4 key business categories, focusing on branded pharmaceuticals, vaccines, and therapeutics, with approximately 70% of India-sold products manufactured domestically. Pfizer Limited generated Q3 FY26 revenue of Rs 645.03 crore (up 19.8% YoY) and Q4 FY26 revenue of Rs 629 crore, operating with a zero-debt balance sheet, 63.46% ROCE, and 35%+ profit margins.

The company uses a hybrid go-to-market combining enterprise field sales targeting hospitals and healthcare professionals (supported by the PfizerPro.in portal) with an exclusive supply and marketing agreement with Cipla Limited for legacy brands Corex Dx, Corex LS, Dolonex, and Neksium. Recent strategic activity includes the December 2025 launch of Rimegepant ODT in the anti-migraine category, hospital partnerships for adult vaccination (Artemis Hospitals), and the Arogya Seva Kendras CSR initiative with Star Health and Piramal Swasthya covering 9 Indian states. Customer segments span end-patients across multiple therapeutic conditions, healthcare professionals served through dedicated medical-information channels, and specialty care patients in categories such as migraine. Pfizer Limited is operationally influenced by global Pfizer Inc. decisions, including a December 2025/FY26 personnel restructuring with Rs 41.73 crore in exceptional separation costs and parent-level divestiture of Haleon in March 2025.

Pfizer firmographics

Firmographics
Name
Pfizer
Legal name
Pfizer Limited
Website
https://pfizerindia.com
Company type
Public
Founded year
1950
Operating status
Operating
Headcount range
10,001+ employees
Short description
Pfizer Limited is the Indian subsidiary of Pfizer Inc., marketing 150+ branded pharmaceutical products across 15 therapeutic areas, including vaccines and specialty therapeutics, serving Indian patients and healthcare professionals through field sales, the PfizerPro.in portal, and a Cipla distribution partnership.
Ownership category
akta.pro rank

Pfizer industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Pharmaceutical manufacturing
  • Prescription medicines
  • Vaccines and therapeutics
  • Branded generic drugs
  • Anti-migraine therapy

Where Pfizer is headquartered

Location

Headquarters

HQ city
Mumbai
HQ country
India
HQ region
Asia

Offices1 record

Markets served

Pfizer business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Pfizer India generates revenue through the sale of pharmaceutical products across 15 therapeutic areas with over 150 products in 4 key business categories. The company has a strong focus on branded products, vaccines, and therapeutics.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Pfizer product offering

Product offering

Core offering

Pfizer Limited manufactures and markets a portfolio of more than 150 pharmaceutical products across 15 therapeutic areas through 4 key business categories, including branded medicines, vaccines, and therapeutics. Its offerings include the anti-migraine medication Rimegepant ODT launched in December 2025 and brands such as Corex Dx, Corex LS, Dolonex, and Neksium distributed through an exclusive supply and marketing agreement with Cipla.

Product overview

Pfizer Limited operates as a pharmaceutical company offering a diverse portfolio of over 150 products across 15 therapeutic areas through 4 key business categories. The product portfolio includes branded pharmaceutical products such as migraine medication (Rimegepant ODT), and brands under strategic partnerships (Corex Dx, Corex LS, Dolonex, Neksium via Cipla agreement). The company focuses on vaccines and therapeutics, with products spanning multiple therapeutic categories.

Differentiator

Problem solved

Functional benefit

Products and services

  • Rimegepant ODT Anti-migraine medication for adults with insufficient response to triptan drugs, sold to healthcare providers and dispensed to patients in India.
  • Corex Dx Pharmaceutical brand under exclusive supply and marketing agreement with Cipla Limited in India.
  • Corex LS Pharmaceutical brand under exclusive supply and marketing agreement with Cipla Limited in India.
  • Dolonex Pharmaceutical brand under exclusive supply and marketing agreement with Cipla Limited in India.
  • Neksium Pharmaceutical brand under exclusive supply and marketing agreement with Cipla Limited in India.
  • Pfizer Limited Product Portfolio Comprehensive portfolio of more than 150 branded pharmaceutical products across 15 therapeutic areas and 4 key business categories, including vaccines, therapeutics, and other branded medicines sold to healthcare providers in India.

Quantifiable outcome

  • 19.8% YoY revenue growth in Q3FY26
  • +3 more outcomes

Companies that use Pfizer

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Pfizer technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Pfizer partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and major.

  • Star Health and Allied Insurance Company LimitedcoreStrategic or Co-development Partner · 25 February 2026Pfizer India is contributing vaccination expertise to Star Health's Arogya Seva Kendras CSR program, providing free primary healthcare including adult pneumococcal vaccination. The initiative operates across 9 Indian states including Chennai, Mysuru, Hyderabad, Bhubaneswar, Punjab, UP, West Bengal, and Maharashtra.
  • Piramal SwasthyacoreStrategic or Co-development Partner · 25 February 2026Partnership with Piramal Swasthya for the Arogya Seva Kendras initiative under Star Health's CSR program to provide free primary healthcare services to over a million lives.
  • Cipla LimitedcoreChannel Partner/ Reseller/ Distributor · 19 December 2025Exclusive supply and marketing agreement with Cipla Limited for Pfizer's brands Corex Dx, Corex LS, Dolonex, and Neksium. This partnership includes exceptional costs of Rs 41.73 crore for personnel separation linked to this agreement.
  • Summit TherapeuticsmajorStrategic or Co-development Partner · 24 February 2025Pfizer to test Summit Therapeutics' bispecific with ADCs as part of cancer treatment development collaboration. Partnership evaluated for potential in cancer drug development.
  • PAHO, Argentina, SinergiummajorStrategic or Co-development Partner · 15 January 2025Pfizer partnership with PAHO, Argentina, and Sinergium to drive local production of 20-valent pneumococcal vaccine for Latin America and the Caribbean.
  • Artemis HospitalscoreStrategic or Co-development Partner · 7 August 2024Launch of Centre for Adult Vaccination with Artemis Hospitals, providing specialized vaccination services for adults including pneumococcal vaccination.

Scale indicators16 records

Recent moves7 records

Expansion highlights6 records

Pfizer competitors and assessment

Company assessment

Direct peers

  • Cipla Limited: India's largest domestic pharma company by some metrics and Pfizer India's exclusive distribution partner since December 2025 for Corex Dx, Corex LS, Dolonex, and Neksium. Directly comparable business model with branded generics across multiple therapeutic areas in India.
  • Glenmark Pharmaceuticals: India-domiciled pharma with branded specialty/generic portfolio. Comparable in therapy-area breadth and HCP field-sales model, though typically positioned at a smaller revenue scale than Pfizer India.
  • Dr. Reddy's Laboratories: Major Indian-headquartered pharma with a comparable branded generics portfolio plus emerging specialty/biologics presence. Competes directly with Pfizer India in cardiology, oncology, and primary care therapy areas.
  • Lupin Limited: Top-5 Indian pharma with branded and generic formulations across cardiovascular, diabetes, and respiratory areas. Directly comparable in scale, India-centric commercial model, and HCP-targeted field sales motion.
  • Torrent Pharmaceuticals: Mid-cap Indian pharma with branded formulations across therapeutic areas. Comparable in size, branded-generic strategy, and India-focused commercial execution to Pfizer Limited India.
  • Sun Pharmaceutical Industries: India's largest pharmaceutical company by revenue, with a comparable branded formulations portfolio spanning multiple therapeutic areas. Both companies compete for the same HCP mind-share and retail pharmacy shelf space across India.
  • Abbott India Limited: Indian subsidiary of Abbott Laboratories with a nearly identical structural profile to Pfizer Limited: MNC pharma subsidiary, broad therapy-area branded portfolio, and NSE/BSE-listed public company. Direct comparable for MNC pharma India model analysis.
  • GSK Pharmaceuticals India (now part of Hetero/BSV): MNC pharma subsidiary operating in India with branded specialty and vaccine portfolios. Closely mirrors Pfizer India's MNC pharma India business model, including vaccines and specialty launches.
  • Novartis India: Indian arm of Novartis with specialty pharma focus including neurology and cardiology. Comparable as a Swiss MNC pharma subsidiary operating in India with similar portfolio breadth and HCP-engagement model.
  • Sanofi India: MNC pharma subsidiary with similar branded specialty franchises including diabetes/cardiovascular. Operates with comparable India-focused commercial structure, HCP sales force, and listed-entity dynamics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Pfizer social profiles

Digital presence

Pfizer financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pfizer leadership team

Management profile

Number of profiles

Profiles4 records

Pfizer funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pfizer M&A and investment

M&A and investment

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pfizer

What does Pfizer do?

Pfizer Limited manufactures and markets a portfolio of more than 150 pharmaceutical products across 15 therapeutic areas through 4 key business categories, including branded medicines, vaccines, and therapeutics. Its offerings include the anti-migraine medication Rimegepant ODT launched in December 2025 and brands such as Corex Dx, Corex LS, Dolonex, and Neksium distributed through an exclusive supply and marketing agreement with Cipla.

Is Pfizer a public or private company?

Pfizer is a public company. It is classified as public and is currently operating.

When was Pfizer founded?

Pfizer was founded in 1950. It employs 10,001+ people.

Where is Pfizer based?

Pfizer is headquartered in Mumbai, India, in the Asia region.

How does Pfizer make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Pfizer's main competitors?

Direct peers on record are Cipla Limited, Glenmark Pharmaceuticals, Dr. Reddy's Laboratories, Lupin Limited, Torrent Pharmaceuticals, Sun Pharmaceutical Industries, Abbott India Limited, GSK Pharmaceuticals India (now part of Hetero/BSV), Novartis India and Sanofi India.

Does Pfizer have an API?

No public API is recorded for Pfizer.

What industry is Pfizer in?

Pfizer's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business TodayPfizer India’s Meenakshi Nevatia on making new therapies more accessible - BusinessTodayMeenakshi Nevatia, Pfizer India's MD, is prioritizing new therapies, affordability, and partnerships to expand the business. She advanced launches in multiple myeloma, vaccines, migraine, and anti-infectives, and plans to use AI and support 40+ start-ups via Pfizer INDovation.The Times of IndiaPfizer India speaks up after Karnataka FDA crackdown, says patient safety is top priorityPfizer India said patient safety is its top priority after Karnataka FDA cancelled 16 drug licences and suspended eight others over spurious medicines. The crackdown followed a raid that seized drugs, machinery, and printing materials worth about Rs 5.05 crore, with a criminal case filed under the Drugs and Cosmetics Act.BusinessLinePfizer India removes products from Karnataka markets after spurious drugs crackdownPfizer India removed products from Karnataka markets after the state's spurious drugs crackdown, including suspending its depot in Nelamangala. The company said it removed batches with copied batch numbers to avoid confusion and is working with authorities to resolve queries.https://www.outlookbusiness.com/Patient Safety Top Priority, Working With Authorities On Counterfeit Medicine Probe: Pfizer India – Outlook BusinessPfizer India said patient safety and product quality are its highest priorities, responding to Karnataka FDA action on counterfeit drugs. The regulator cancelled 16 drug licences and suspended eight others after an inspection seized spurious drugs and printing materials worth ₹5.05 crore. Pfizer has been cooperating with authorities for a month, removing affected batches and providing technical information.BusinessLinePatient safety top priority, working with authorities on counterfeit medicine probe: Pfizer IndiaPfizer India said patient safety and product quality are its highest priorities, responding to Karnataka FDA action on counterfeit drugs. The regulator cancelled 16 drug licences and suspended eight others after an inspection seized spurious medicines and printing materials valued at Rs 5.05 crore. Pfizer has been cooperating with authorities for a month.The Times of IndiaPfizer India speaks up after Karnataka FDA crackdown, says patient safety is top priorityPfizer India said patient safety and product quality are its top priorities after Karnataka FDA cancelled 16 drug licences and suspended eight others over counterfeit medicines. The crackdown followed an August 18 raid that seized spurious drugs, machinery, and printing materials worth about Rs 5.05 crore. Pfizer has been cooperating with authorities for a month.The Times of IndiaBengaluru drug scam: Rs 12cr spurious Pfizer stock sold to hospitals since Feb 2025; kingpin among 8 heldKarnataka health minister UT Khader ordered suspension of an assistant drug controller for failing to lock Krupa Health Care's wholesale pharmacy after Veeresh Kumar Jain's arrest. FDA cancelled 16 pharmacy licences and suspended eight others, including a Pfizer depot, after finding spurious drugs seized from a Bidadi farmhouse. No adverse drug reactions have been reported so far.Deccan HeraldKarnataka cancels 16 drug licences of retailers, wholesalers over spurious medicines; suspends 8 including Pfizer depotKarnataka cancelled 16 drug licences of retailers and wholesalers and suspended 8, including a Pfizer depot, over spurious medicines. The crackdown followed a month after the FDA's Drug Enforcement Wing busted a large-scale spurious drug racket in Bidadi, seizing counterfeit medicines and industrial machinery valued at over Rs 5 crore.The HinduFDA cancels 16 pharmacy licences, suspends 8, including Pfizer depotKarnataka's FSDA cancelled 16 pharmacy licences and suspended 8, including Pfizer's depot in Nelamangala, over a drug repacking racket. The department seized ₹5.05 crore worth of spurious drugs and machinery from a Bidadi farmhouse. Health Minister U.T. Khader said Pfizer's sale was stopped due to non-cooperation.The Times of IndiaFake drugs: Karnataka cancels 16 licenses, suspends 8 including that of Pfizer depotKarnataka FDA cancelled 16 drug licenses and suspended 8, including Pfizer C&F Depot, after raids on a repackaging operation. The operation allegedly procured low-cost medicines, relabeled them as expensive branded drugs, and used non-functional QR codes. The seized stock is under lab analysis, and a criminal case has been filed.